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A hat trick of new epigenetic clocks have recently been 
published by Horvath et al.: The Skin & Blood clock [1] 
provides a more precise estimation of chronological age 
in tissues and cell types frequently used in research and 
forensics, while PhenoAge [2] and GrimAge [3] aim to 
capture biological aging and derive an improved 
prediction of mortality and morbidity risks. Together, 
these new epigenetic clocks present valuable tools to 
investigate human aging, shed light on the question of 
why we all age differently, and develop strategies to 
extend human life- and healthspan. 
In 2013, the first epigenetic age estimation method that 
works with high accuracy across almost all human 
tissues and cell types was published by Steve Horvath 
[4]. The publication of this multi-tissue clock marked a 
milestone in epigenetics and aging research, and since 
then, numerous studies have confirmed not only its 
ability to accurately estimate an individual’s age but 
also the clock’s great value for studying the human 
aging process. 
Horvath’s multi-tissue clock is based on DNA 
methylation data. DNA methylation, the addition of 
methyl groups to cytosine bases of the DNA, is the most 
widely studied epigenetic modification so far. It plays 
an important role in the regulation of gene expression, 
altering the phenotype without changing the genotype. 
A particular locus in the genome can either be 
methylated or unmethylated. But as DNA methylation 
measurements are usually obtained from a pool of tens 
of thousands of cells, what is measured, is the 
proportion of the cells in which a locus is methylated. 
These proportions are given in β-values between 0 
(unmethylated in all cells) and 1 (methylated in all 
cells). Thus, methylation β-values effectively measure 
cell-to-cell variability within a sample. 
In many positions of the human genome, this 
methylation heterogeneity changes with age. These 
usually small but consistent age-associated changes in 
DNA methylation are what make the epigenetic clock 
work. And it works very precisely, with a median 
absolute error (MAE) of only 3.6 years, clearly out-
performing previously used molecular biomarkers of 
age such as telomere length [4,5]. 
However, deviations of the age estimation derived by 
DNA methylation compared to chronological age do 
also provide valuable information. There is significant 
interindividual variability present in the human aging  
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process [6–8]. Biological aging occurs at different rates 
across individuals who can exhibit considerably distinct 
physical fitness and age-related disease susceptibilities 
despite being the same chronological age. The epi-
genetic clock has intriguingly demonstrated to be able 
to quantify these differences and give a biologically 
relevant prediction of age, that is, a measurement of 
biological or physiological age. DNA methylation age 
predicts all-cause mortality better than chronological 
age, and it has also been associated with physical and 
mental fitness, vegetable and fish intake, obesity, 
smoking, alcohol use, lifetime stress, social class and 
multiple other factors [5,9]. 
Recently, three further improved epigenetic clocks were 
published: The Skin & Blood clock [1], DNA methyla-
tion PhenoAge [2], and DNA methylation GrimAge [3]. 
While the latter two aim to provide an improved pre-
diction of mortality and are more closely related to 
physiological dysregulation, the Skin & Blood clock 
gives an even more accurate prediction of chronological 
age of easily accessible human tissues – for example, 
whole blood, saliva and skin – and cell types often used 
in research such as fibroblasts and lymphoblastoid cell 
lines. 
In a set of whole blood samples, the application of the 
Skin & Blood clock resulted in age estimations with a 
MAE of 2.5 [1]. The correlation between chronological 
age and estimated age also improved correspondingly, 
from a Pearson’s r of 0.96 for the multi-tissue clock to 
0.98 in the Skin & Blood clock [1]. 
We observed similar results when we applied the 
Skin & Blood clock, the multi-tissue clock, and the 
PhenoAge clock to a dataset of 656 samples (age range 
19 to 101 years) with which another highly accurate 
epigenetic age estimator for whole blood samples was 
developed by Hannum et al. [10] [of note, we did not 
include GrimAge in these comparisons, as GrimAge is 
supposed to be a predictor of mortality rather than an 
age predictor and takes (chronological) age itself as 
input, together with sex and DNA methylation measure-
ments]. The Skin & Blood clock exhibited the least 
error and the best correlation with chronological age 
(see Table 1, and Figure 1), confirming its improved 
performance in chronological age prediction. 
The high sensitivity of the Skin & Blood clock in the 
above-mentioned cell types makes it particularly in-
teresting for ex vivo experiments, as it provides a critical 
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advantage over the multi-tissue clock which does not 
work well in fibroblasts and epithelial cells, and can 
track the dynamic aging of cells in culture [1,4]. 
Age estimations closer to the individuals’ chronological 
ages could nonetheless also lead to decreased possibi-
lities for the biomarker to capture biological aging. 
However, there is still considerable variation regarding 
the deviation from chronological age observable (See 
Table 1 and Figure 1), and the Skin & Blood clock is 
highly predictive of time to death across multiple 
epidemio-logical cohort studies [1]. 
Notwithstanding, the best epigenetic mortality predictor 
reported so far is DNA methylation GrimAge [3], a 
composite biomarker based on DNA methylation 
surrogates for several blood plasma protein markers and 
smoking pack-years as well as chronological age and 
sex. This new epigenetic clock not only performs better 
in predicting time to death, time to coronary heart 
disease and time to cancer as compared to other epi-
genetic clocks but also shows associations with lifestyle 
factors and related variables that could not be observed 
with previous epigenetic clocks.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For example, a beneficial effect of physical exercise on 
GrimAge is reported. GrimAge also shows negative 
associations with vegetable and carbohydrate consump-
tion and Omega-3 acid intake. Increased GrimAge – on 
the contrary – is associated with fat intake, insulin and 
glucose levels, and BMI and waist-to-hip ratio. 
Interestingly, GrimAge also shows a strong correlation 
with measures of adiposity derived by computed 
tomography, in particular regarding liver fat and 
visceral adipose tissue volume which are known to be 
detrimental to health. Altogether, these associations 
make DNA methylation GrimAge a promising bio-
marker for human health and physiological age. 
While epigenetic clocks such as PhenoAge and 
GrimAge already provide valuable readouts of bio-
logical aging, the next challenge will be to develop 
epigenetic predictors that can distinguish between 
different reasons for increased (or decreased) mortality 
and morbidity. Specific risks for different diseases or 
disease types could be incorporated into assessments for 
individuals with altered epigenetic ages, possibly 
providing opportunities for better disease prevention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1. Comparison of the epigenetic age estimation of three different clocks.  
Clock Pearson’s r p-value Median error Maximum 
error 
Skin & 
Blood 
0.94 5.03E-308 3.83 32.20 
Multi-tissue 0.92 1.58E-259 3.84 39.08 
PhenoAge 0.85 5.10E-186 7.88 47.56 
 Errors given in absolute numbers. 
 
 
Figure 1. Comparison of epigenetic age estimations derived by three different epigenetic clocks. Each grey data 
point represents an individual whole blood sample, ordered by the chronological age of the sample donor from young to 
old. The coloured symbols show the epigenetic age estimation provided by the three clocks, where yellow represents the 
Skin & Blood clock, magenta the multi-tissue clock, and green the PhenoAge clock. The Skin & Blood clock’s age estimations 
come closest to the corresponding chronological ages. However, as the multi-tissue clock, it tends to show slightly 
increased epigenetic ages in younger individuals and decreased epigenetic ages in the elderly, while the PhenoAge clock 
predicts younger ages (in terms of life- and healthspan) for most individuals in the dataset used here [10]. 
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Despite providing the most accurate molecular 
biomarkers of age to date, it remains a mystery why 
exactly the epigenetic clocks work, and whether age-
related changes in DNA methylation contribute to the 
cause of aging or are a result of it. It has been hypo-
thesized that the changes giving rise to DNA 
methylation age estimators are the molecular footprints 
of epigenetic developmental and maintenance programs, 
thus capturing at least a part of the biological aging 
mechanism [4–7]. This is an attractive hypothesis, as 
epigenetic changes are, in principle, reversible. 
Epigenetic clocks have already proven to be an 
invaluable tool in determining the impact of different 
factors on aging. With their further developments, they 
provide an easily measurable outcome to evaluate and 
monitor interventions aimed to promote healthy aging, 
in both in vitro experiments and by tailoring lifestyles 
individually through personalized medicine and preven-
tive health care [6,8]. How the latter can be im-
plemented appropriately is a subject of intense debate. 
Enabled by its open consent and open access policy, the 
Personalized Genome Project UK [11] has pioneered 
epigenetic reports that inform participants of the project 
about their epigenetic ages. This can help participants to 
reflect on their lifestyles and implement changes to live 
and age healthier. 
As epigenetic clocks are getting more and more 
accurate and informative, they also become promising 
candidates for applications in areas such as forensics, 
immigration and insurance. These new possibilities, 
however, come along with the potential for misuse and 
discrimination, and the current lack of regulation in this 
area needs to be urgently addressed. 
Finally, without the open access movement, the 
development of epigenetic clocks would not have been 
possible (the first multi-tissue epigenetic clock was 
based on 8,000 openly available DNA methylation 
samples) [4,5], and with ever more data available, we 
will be able to continue to shed light on the complex 
phenotype of human aging. To this aim, collaboration 
across different disciplines will be indispensable, 
through the integration of electronic health records with 
detailed multi-omic data and deep phenotypes from 
longitudinal population cohorts and clinical studies. 
Epigenetic clocks will be key players in this process. 
And by providing insight into the question of why we 
all age differently and assisting the development and 
monitoring of strategies to extend life- and healthspan, 
the epigenetic clock may indeed become a molecular 
crystal ball for human aging. 
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